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Abstract
Cl-IB-MECA is a selective A3 adenosine receptor agonist, which plays a crucial role in limiting tumor progression. In mice, Cl-
IB-MECA administration enhances the anti-tumor T cell-mediated response. However, little is known about the activity of Cl-
IB-MECA on CD8+ T cells. The aim of this study was to investigate the effect of ex vivo Cl-IB-MECA treatment of CD8+ T cells,
adoptively transferred in melanoma-bearing mice. Adoptive transfer of Cl-IB-MECA-treated CD8+ T cells or a single
administration of Cl-IB-MECA (20 ng/mouse) inhibited tumor growth compared with the control group and significantly
improved mouse survival. This was associated with the release of Th1-type cytokines and a greater influx of mature
Langerin+ dendritic cells (LCs) into the tumor microenvironment. CD8+ T cells treated with Cl-IB-MECA released TNF-a
which plays a critical role in the therapeutic efficacy of these cells when injected to mice. Indeed, neutralization of TNF-a by
a specific monoclonal Ab significantly blocked the anti-tumor activity of Cl-IB-MECA-treated T cells. This was due to the
reduction in levels of cytotoxic cytokines and the presence of fewer LCs. In conclusion, these studies reveal that ex vivo
treatment with Cl-IB-MECA improves CD8+ T cell adoptive immunotherapy for melanoma in a TNF-a-dependent manner.
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Introduction
Melanoma is the most aggressive skin tumor with high
metastatic potential and only a 5% 5-year survival rate for
patients with metastatic disease [1,2]. The main feature of
melanoma is the resistance to most chemotherapeutics [3].
Adoptive transfer of T cells is currently a promising anti-tumor
therapy in patients with melanoma and many studies have
generated functional T cells capable of mediating tumor regression
in vivo [4–9].
Adenosine is a potent regulator of tumor immune-surveillance
[10] and exerts its effect through four receptor subtypes: A1 and
A3 receptors are Gi/o-coupled receptors that decrease intracel-
lular cyclic AMP (cAMP) whilst A2a and A2b are Gs-coupled
receptors that increase intracellular cAMP levels [11]. Increasing
evidence shows that activation of different adenosine receptors
might exhibit opposing outcomes on immune cell function: A2a
and A2b receptors typically suppress cell responses, whilst A1 and
A3 receptors promote cell activation [12]. A2a receptor activation
critically impaired T cell function during activation, by reducing
cytokine and chemokine production, which in turn facilitates
tumor growth [10,13–16]. However, little is known about the
effect of adenosine A3 receptor agonists on T cells, which express
the A3 receptor [17].
The A3 receptor plays a critical role in restricting tumor
progression. Indeed, pharmacological activation of A3 receptor by
its selective agonist Cl-IB-MECA arrests cell cycle progression of
many cancerous cell lines and inhibits tumor growth in mice [10].
Furthermore, A3 receptor agonists enhance the anti-tumor activity
of natural killer (NK) cells and increases serum levels of IL-12 in
the mouse [18]. We have recently demonstrated that Cl-IB-
MECA administration into mice can induce an efficient T cell
response that could critically affect tumor growth [19].
In this study we sought to investigate whether Cl-IB-MECA-
treated CD8+T cells are effective at controlling tumor growth.
Here, we show that CD8+T cells, treated in vitro with Cl-IB-
MECA, adoptively transferred into melanoma-bearing mice
suppressed tumor growth. In addition, a single local injection of
Cl-IB-MECA significantly reduced melanoma growth, facilitating
a Th1-like and cytotoxic immune response in the tumor lesions.
CD8+ T cells treated with Cl-IB-MECA secrete TNF-a which is
crucial for the observed anti-tumor effects in mice.
Materials and Methods
Mice and Cell culture
C57Bl/6j and Athymic Nude-Foxn1nu mice were purchased
from Harlan Laboratories (Udine, Italy) and maintained in specific
pathogen-free conditions in the Animal Facilities of the National
Cancer Institute ‘‘G.Pascale’’ of Naples (Italy). This study was
carried out in strict accordance with the recommendations in the
Institutional animal care guidelines, Italian D.L. no. 116 of 27
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January 1992 and European Communities Council Directive of 24
November 1986 (86/609/ECC). The ethics committee of
Pharmaceutical and Biomedical Department of the University of
Salerno approved this study.
B16-F10 mouse melanoma cell line was purchased from
American Type Culture Collection (LGC Standards S.r.l., Milan,
Italy) and cultured in DMEM supplemented with 10% FBS, L-
Glutamine (2 mM), penicillin (100 U/ml) and streptomycin
(100 U/ml) (Sigma-Aldrich, Milan Italy).
Isolation and treatment of CD8+ T cells
CD8+ T cells were purified from the spleens of naı¨ve C57Bl6j
mice by magnetic separation using a CD8+ T cell isolation kit
(negative selection, EasySep Stem Cell, Voden, Milan, Italy).
Purity of CD8+ T cells was checked by flow cytometry after
staining with a PE-conjugated anti-CD8 antibody (eBioscience,
CA, USA) and was routinely around 90% (Figure S1). CD8+ T
cells were cultured in RPMI 1640 enriched with 10% FBS and
stimulated with Cl-IB-MECA (0.1 mg/ml; Tocris Cookson Ltd.,
London, UK) for 24 h or 72 h at a density of 106 cells/ml. MRS
1191 (5 mM), an adenosine A3 receptor antagonist was also used.
Cytokine production in supernatants was analyzed by ELISA and
cells were stained with the following markers: CD27-FITC, CD25-
PE, CD69-allophycocyanin and analyzed by FACS analysis. In
some experiments CD8+ T cells were activated with Mouse T-
Activator CD3/CD28 Dynabeads (Invitrogen, Milan, Italy),
according to the manufacturer’s instructions.
Animal protocols
C57Bl6j mice (female at 6–10 weeks of age) were injected
subcutaneously (s.c.) with 36105 B16 melanoma cells per mouse
(0-day). Ten days later (10-day) mice were peritumorally (p.t.)
administered once with Cl-IB-MECA (20 ng/mouse) or PBS
(100 ml) and sacrificed 4 days later.
For the adoptive transfer of CD8+ T cells, tumor-bearing mice
were injected p.t. with 16106 CD8+ T cells per mouse (in 100 ml
PBS). Adoptively transferred CD8+ T cells were treated overnight
with Cl-IB-MECA (0.1 mg/ml) or PBS, washed twice in PBS and
immediately injected into melanoma-bearing mice. Tumor growth
was monitored by measuring the perpendicular diameters by
means of a calliper (Stainless Hardened, Ted Pella, Inc. CA, USA)
and calculated by the formula 4/3 p6(long diameter/2)6(short
diameter/2)2. For survival rate experiments, s.c. tumor volume
was daily monitored and mice were be euthanized according to
the animal care protocol when the tumor reached ,2000 mm3 in
volume. Melanoma tissues and proximal lymph nodes were
isolated for further analyses.
In some experiments, a neutralizing monoclonal antibody
(mAb) against TNF-a (mouse IgG Clone MP6-XT3, 10 mg/
mouse; eBioscience, San Diego, CA, USA) [20] was injected i. p.
every day, starting from day 10 when mice received Cl-IB-MECA
alone or CD8+ T cells as described above. The anti-TNF-a mAb
reduced levels of TNF-a detection by 95% compared with IgG
(data nor shown).
Flow Cytometry Analysis
Tumors and lymph nodes were harvested from mice after
adoptive transfer and digested by collagenase A (1 U/ml) (Sigma-
Aldrich, Milan, Italy). Samples were passed through 70-mm cell
strainers and red blood cells were lysed. Cell suspensions were used
for flow cytometric analyses (BD FacsCalibur, Milan, Italy). The
following antibodies were used: CD8-PE, NK1.1-PE, CD3-
PeCy5.5, CD11c-FITC, CD11b-PeCy5.5, F4/80-PE, CD4-FITC,
CD207-PE or CD207- allophycocyanin, CD80-PE, MHC I-
PeCy5.5 (eBioscience, San Diego, CA, USA). The stained cells
were analysed by using Becton Dickinson FACScan flow
cytometer.
ELISA
TNF-a, IFN-c and Granzyme B were detected in melanoma
tissue homogenates and cell surnatants using a mouse specific
ELISA kits (eBioscience, San Diego, CA, USA).
Immunohistochemistry
For histological analysis, frozen tumor specimens were fixed
with acetone, permeabilized with methanol, and stained with
Hematoxilin and Eosin (H&E staining) according to standard
procedures. Additional frozen sections were stained with Ki67
(Abcam, Cambridge, UK) or Granzyme B (Invitrogen, Milan,
Italy) and detected with FITC-labeled anti-rabbit or FITC-labeled
anti mouse secondary antibodies, respectively. In all staining
experiments, isotype-matched IgG and omission of the primary
antibody was used as negative controls. Tissue sections were
stained for the presence of apoptosis using the TUNEL apoptosis
kit (BioVision, CA, USA) according to the manufacturer’s
instructions. Melanoma sections were read in a blinded manner
by two independent investigators. Labeled cells were counted per
visual field and expressed as the number of TUNEL+ cells per
mm2 6 SEM (n = 5 for each tissue) by means of Axioplan Imaging
Programme (Carl Zeiss).
Analysis of RNA
Total RNA from isolated CD8+ T cells was prepared using an
RNASPIN MINI extraction kit according to the manufacturer’s
instructions (GE Healthcare, Milan, Italy). Reverse transcription
was performed by using a first-strand cDNA synthesis kit (GE
Healthcare) followed by PCR. Thermal cycling conditions were
5 min at 95uC, followed by 35 cycles of 45 sec at 94uC, 20 sec at
58uC, 30 sec at 72uC. The A3 receptor primer pairs were as
follows:
Forward 59- GTTCCGTGGTCAGTTTGGAT -39
Reverse 59- GCGCAAACAAGAAGAGAACC -39.
Statistical analysis
Results are expressed as mean 6 SEM. All statistical differences
were evaluated by either Student’s t test or one way ANOVA as
appropriate. To assess survival rate, the Kaplan-Mayer model was
used, and comparison of survival between groups was performed
using the log-rank test with Prism4 software (GraphPad Software,
La Jolla, CA). P values less than 0.05 were considered statistically
significant.
Results
Adoptively transferred CD8+ T cells treated with Cl-IB-
MECA suppress melanoma growth
We assessed whether CD8+ T cells, treated in vitro with Cl-IB-
MECA, have the capacity to control melanoma growth. CD8+ T
cells, isolated from the spleen of naı¨ve C57Bl6j mice, were treated
overnight with Cl-IB-MECA (0.1 mg/ml) or PBS. Mice bearing
B16 melanoma were adoptively transferred with Cl-IB-MECA- or
PBS-treated CD8+ T cells (16106 cells/mouse) at day 10 after
tumor implantation (Figure 1A). We found that adoptively
transferred CD8+ T cells treated with Cl-IB-MECA significantly
suppressed tumor growth compared with groups receiving T cells
cultured without Cl-IB-MECA (untreated CD8+ T cell transfer) or
controls (no adoptive transfer) (Figure 1B). The decrease in tumor
Cl-IB-MECA-Treated CD8+ T Cells Inhibit Melanoma
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growth was also verified by H&E staining (Figure S2A) and by
Ki67 staining of melanoma sections (Figure S2B). The route of
adoptive transfer of cells did not affect the ability of Cl-IB-MECA-
treated cells to modulate tumor growth since a similar response to
that described above was observed when cells were delivered by
the i.v. route (Figure S3).
We also tested the anti-tumor activity of Cl-IB-MECA injected
once into melanoma-bearing mice by peritumoral injection, which
is an important route of administration to evaluate directly the
effect of Cl-IB-MECA on tumor growth. We observed that mice
receiving a single injection of Cl-IB-MECA (20 ng/mouse) showed
a significant reduction in tumor growth compared with control
mice (Figure 1B). In line with our previous data [19], this effect
was associated with an increased number of tumor-infiltrating
CD8+ T cells (Figure S4).
In addition, we adoptively transferred Cl-IB-MECA-cultured or
control CD8+ T cells in melanoma-bearing mice and monitoring
survival. Mice had to be euthanized according to the animal care
protocol when tumor reached .,2000 mm3 in volume. Mice
injected with Cl-IB-MECA-treated CD8+ T cells showed a
prolonged survival compared to mice injected with untreated
CD8+ T cells or control groups (p,0.001). Specifically, 50% of
control mice were alive at day 15, whereas 50% of mice adoptively
transferred with Cl-IB-MECA-treated CD8+ T cells survived until
day 21 (Figure 1C). Moreover, a single administration of Cl-IB-
MECA alone was sufficient to improve survival (p,0.05) (50% of
mice survived at day 19) (Figure 1C).
In vivo effectiveness of Cl-IB-MECA-treated CD8+ T cells
in melanoma
We then characterized the in vivo effectiveness of Cl-IB-MECA-
treated CD8+ T cells in melanoma. TNF-a levels in melanoma
tissue of mice adoptively transferred with Cl-IB-MECA-treated
CD8+ T cells or mice injected once with Cl-IB-MECA were
significantly increased compared with control groups (Figure 2A).
Moreover, levels of granzyme B in melanoma tissue were elevated
in mice adoptively transferred with Cl-IB-MECA-treated CD8+ T
cells compared with those injected with untreated CD8+ T cells or
PBS (Figure 2B).
We also analyzed apoptosis within the melanoma tissue. The
number of TUNEL+ cells was increased in melanoma tissue
harvested from mice adoptively transferred with Cl-IB-MECA-
treated CD8+ T cells compared to that observed in untreated
CD8+ cell transfer or controls (Figure 2C and D).
Cl-IB-MECA-treated CD8+ T cells reduce tumor
outgrowth in Nude mice
To examine the role of CD8+ T cells treated with Cl-IB-MECA
in tumor immunotherapy, we used Nude mice, which lack of T
cells, bearing 10-day B16 tumors. Nude mice that received CD8+
Figure 1. Adoptive transfer of CD8+ T cells cultured with Cl-IB-MECA mediates enhanced tumor suppression in melanoma-bearing
mice. A) C57Bl6j mice were s.c. inoculated with 2.56105cells B16-F10 cells/mouse. 10 days after B16 injection, mice received a single p.t. injection of
Cl-IB-MECA (20 ng/mouse) or 16106 CD8+ T cells/mouse treated with Cl-IB-MECA (0.1 mg/ml) or 16106 untreated CD8+ T cells/mouse or PBS (Ctr). B)
Tumor volume (mm3) measured in control mice (Ctr, n = 11) and mice receiving a single dose of Cl-IB-MECA (n = 13) or adoptively transferred with Cl-
IB-MECA-treated CD8+ T cells (n = 14) or with untreated CD8+ T cell (n = 10). C) Increased survival of melanoma-bearing mice receiving Cl-IB-MECA
(p,0.05) or CD8+ T cell transfer cultured with Cl-IB-MECA (p,0.001) compared with control groups (n = 5/group). Data are from three independent
experiments and represent mean6 SEM. Statistical differences were determined by one way ANOVA and Student’s t test, as appropriate. ***p,0.001.
Comparison of survival between groups was performed using long-rank test.
doi:10.1371/journal.pone.0045401.g001
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T cells treated with Cl-IB-MECA, as described above, had a
significant reduction in tumor size compared with animals
receiving untreated CD8+ T cells or control animals (no adaptive
transfer) (Figure 3A). Notably, tumor growth in Nude mice
receiving Cl-IB-MECA alone was similar to that observed in the
control group (Figure 3A). Moreover, mice injected with Cl-IB-
MECA-treated CD8+ T cells showed a prolonged survival
compared to mice injected with untreated CD8+ T cells or PBS
or Cl-IB-MECA (p,0.01) (Figure 3B). H&E staining and Ki67
staining were also performed in melanoma sections harvested from
melanoma-bearing Nude mice (Figure S2C and D, respectively).
These data suggest that Cl-IB-MECA-treated CD8+T cells are
able to control tumor growth when adoptively transferred into
melanoma-bearing mice and further support the concept that the
anti-tumor activity of Cl-IB-MECA is mediated by CD8+ T cells.
Cl-IB-MECA modulates CD8+T cell function in vitro
The A3 receptor is expressed on T cells and its stimulation
typically activates cell responses as a consequence of reduced
intracellular cAMP levels [10,12]. Figure 4A shows that CD8+ T
cells expressed mRNA coding for the A3 adenosine receptor. Our
observation that treatment of CD8+ T cells with Cl-IB-MECA
significantly improved the efficacy of these cells when adoptively
transferred into melanoma-bearing mice, led us to further
investigate whether Cl-IB-MECA may affect the phenotypic and
functional characteristics of CD8+ T cells. In both resting and
activated conditions, Cl-IB-MECA-treated CD8+ T cells secrete
TNF-a (Figure 4B, white bars) and little IFN-c (Figure 4C, white
bars). These results were confirmed by intracellular staining of
TNF-a. Indeed, 4 h after Cl-IB-MECA stimulation the percentage
of CD8+TNF-a+ cells increased compared with control cells
(1.7560.05 vs 16.360.96%). In vitro, Cl-IB-MECA treatment did
not affect the activation status of CD8+ T cells. The number of
CD8+ CD69+ T cells, CD8+CD25+ T cells and CD8+CD27+ T
cells did not change after Cl-IB-MECA treatment compared with
PBS (Figure 4D, E and F respectively, white bars). The same
experiments were also performed in CD8+ T cells activated with
anti-CD3/CD28. We found no change in the expression of CD69,
CD25 and CD27 (Figure 4D, E and F respectively, black bars) nor
increased levels of TNF-a and IFN-c in activated CD8+ T cells
after Cl-IB-MECA stimulation. Indeed, levels of TNF-a and IFN-
c were similar to those observed in control cells (Figure 4B and C,
black bars).
To verify that the A3 adenosine receptor mediated the effect of
Cl-IB-MECA on TNF-a release in CD8+ T cells, we treated cells
with the A3 receptor antagonist MRS1191 (5 mM) before the
addition of Cl-IB-MECA or PBS. MRS1191 completely blocked
the effect of Cl-IB-MECA on TNF-a production (Figure 4G).
Together, these results suggest that Cl-IB-MECA failed to
directly activate CD8+ T cells, but favors the production of TNF-a
in an A3-dependent manner. Accordingly, we also found that
splenocytes isolated from melanoma-bearing mice treated with Cl-
Figure 2. In vivo effectiveness of CD8+ T cell transfer after Cl-IB-MECA treatment is associated with increased apoptosis rate,
granzyme B and TNF-a release into melanoma lesions. A) and B) TNF-a and granzyme B levels, respectively, detected into tissue homogenates
from mice adoptively transferred with Cl-IB-MECA-stimulated CD8+ T cells or Cl-IB-MECA-treated mice. C) Representative pictures of melanoma
cryosections Tunel stained (FITC) and stained with PI (red). Positive and negative controls are also provided. D) Quantitative analysis of Tunel+ cells
detected in melanoma sections. Results are expressed as mean 6 SEM (n = 5/group). Data are from two independent experiments and represent
mean 6 SEM, n = 6 in each experiment. Statistical difference was determined by one way ANOVA. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0045401.g002
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IB-MECA released increased amounts of TNF-a compared with
splenocytes from control animals (data not shown).
The anti-tumor activity of Cl-IB-MECA-treated CD8+T cells
is dependent on TNF-a
To evaluate the role of TNF-a derived from Cl-IB-MECA-
treated CD8+ T cells, CD8+ T cells were transferred into
melanoma bearing mice receiving a neutralizing monoclonal
antibody (mAb) against TNF-a. For this purpose, mice were
injected with 10 mg/mouse of mAb anti-TNF-a or IgG control
(mouse IgG) every day starting from day 10 after tumor cell
implantation. Mice were administered with Cl-IB-MECA once or
adoptively transferred with untreated CD8+ T cells or Cl-IB-
MECA-treated CD8+ T cells as described above. Tumor growth
in mice treated with anti-TNF-a mAb (dashed lines) was
compared with that measured in mice treated with the IgG
control (continuous lines) (Figure 5A). The administration of the
anti-TNF-a mAb did not alter the tumor growth in melanoma-
bearing control mice (Figure 5A). The capacity to control tumor
growth by transferred Cl-IB-MECA-treated T cells was signifi-
cantly affected in mice receiving the TNF-a mAb (Figure 5A).
Similarly, the anti-tumor effect of Cl-IB-MECA alone was
abrogated in mice injected with TNF-a mAb (Figure 5A). These
data correlated with a reduction of granzyme B within tumor
tissue whereas no reduction in granzyme B levels were seen in
IgG-treated melanoma-bearing mice (data not shown). These
results indicate that TNF-a within the tumor tissue could be
critical for melanoma cell destruction. Analysis of leukocytes in the
melanoma tissue revealed that the percentage of CD11c+
Langerin (CD207) high dendritic cells (LCs, Langerhans cells)
significantly increased in melanoma tissue of mice adoptively
transferred with Cl-IB-MECA-treated CD8+ T cells (Figure 5B
and C; black bar) compared with control mice (Figure 5B and C;
white bar). Moreover, the activation markers CD80 (66.363.2
versus 78.063.6; p,0.05; Figure 5D) and MHC class I
(236.4614.0 versus 261.862.0; p,0.05; Figure 5E) were signif-
icantly increased on LCs of mice adoptively transferred with Cl-
IB-MECA-treated CD8+ T cells. Thus, transfer of Cl-IB-MECA-
treated CD8+ T cells which are able to produce TNF-a, was
associated with a significant recruitment of LCs into the tumor
tissue.
In mice adoptively transferred with Cl-IB-MECA-treated CD8+
T cells the presence of CD11c+CD207+ cells (Figure 5B and C)
and the expression of the activation markers CD80 (78.063.6
versus 51.662.2; p,0.001; Figure 5D) and MHC I (261.862.0
versus 201.869.4; p,0.001; Figure 5E) were significantly reduced
after TNF-a neutralization.
Altogether, these results suggest that TNF-a released from Cl-
IB-MECA-treated CD8+ T cells or after Cl-IB-MECA adminis-
tration induced LCs activation/influx in the melanoma tissue,
which could, in turn, facilitate the T cell responses in vivo.
Discussion
In this study we show that Cl-IB-MECA -treated CD8+ T cells
adoptively transferred into tumor-bearing mice, control melanoma
growth. Cl-IB-MECA is a selective agonist of the A3 adenosine
receptor, which plays a critical role in limiting tumor progression
[10]. A large number of studies have demonstrated the therapeutic
potential of Cl-IB-MECA as an anti-cancer agent due to its ability
to inhibit tumor cell proliferation both in vitro and in vivo [21]. We
have previously demonstrated that Cl-IB-MECA did not affect the
proliferation rate of B16-F10 cells in vitro, but significantly reduced
melanoma growth in mice, favoring a Th1-like immune response
in the tumor microenvironment [19]. Here we show that a single
injection of Cl-IB-MECA efficiently suppress tumor growth in
mice. The anti-tumor activity of Cl-IB-MECA is lost in mice
lacking T cells, further supporting its high potential to positively
affect the T cell-mediated immune response against cancer cells.
This effect was accompanied by increased levels of Th1-like and
cytotoxic cytokines in the tumor milieu, which are critical for anti-
tumor activity in the host [22,23]. The data suggests an indirect
effect on IFN-c expression, perhaps by priming CD8+ T cells,
since Cl-IB-MECA does not affect IFN-c production directly.
Figure 3. Tumor growth is inhibited in Nude mice adoptively transferred with CD8+ T cells stimulated with Cl-IB-MECA. A) Tumor
volume (mm3) measured in melanoma-bearing Nude mice receiving a single dose of Cl-IB-MECA or adoptively transferred with Cl-IB-MECA-treated
CD8+ T cells or with untreated CD8+ T cells. B) Increased survival of melanoma-bearing Nude mice receiving CD8+ T cell transfer, cultured with Cl-IB-
MECA (p,0.01) compared with control groups and Cl-IB-MECA-treated mice (n = 5/group). Data represent mean 6 SEM, n = 6 in each of two
independent experiments. Statistical difference was determined by one way ANOVA. *p,0.05. Comparison of survival between groups was
performed using long-rank test.
doi:10.1371/journal.pone.0045401.g003
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Our results show, for the first time, that Cl-IB-MECA can
influence CD8+ T cells function. Upon Cl-IB-MECA treatment,
these cells significantly reduced tumor growth and improved
survival when adoptively transferred into melanoma-bearing hosts.
The reduction of tumor growth was associated with higher TNF-a
and granzyme B production, which are both known to induce
programmed cell death [24]. The superior anti-tumor activity of
these cells was also shown in melanoma-bearing Nude mice.
Numerous studies have programmed CD8+ T cells to release
IFN-c in vitro as this is associated with an effector phenotype
[8,25,26]. These criteria are generally sufficient to predict anti-
tumor activity in vivo on adoptive transfer, although the acquisition
of full effector function in vitro impairs in vivo anti-tumor efficacy
[27]. It has also been reported that the effectiveness of adoptively
transferred T cells in vivo can be independent of IFN-c production
and is correlated with other effector cell functions, such as
production of cytotoxic mediators including TNF-a, perforin and
FasL [28–32]. Under our experimental conditions, CD8+ T cells
stimulated in vitro with Cl-IB-MECA secrete TNF-a, but not IFN-
c. Our data, therefore, supports the concept of an indirect effect of
Cl-IB-MECA on CD8+ T cell IFN-c-production.
T cells may produce toxic cytokines, such as TNF-a, which are
able to induce apoptosis [29,30,32]. However, in addition to its
well-defined role in apoptosis, TNF-a can critically affect the
immune response at tumor sites. TNF-a is indeed critical for the
anti-tumor T cell immunity in mice and is required for the optimal
functional T cell response to tumors [33]. The effects of adoptively
transferred Cl-IB-MECA-treated CD8+T cells in vivo could,
therefore, be due to a locally released cytokines, such as TNF-a,
in the tumor microenvironment. TNF-a could induce a local
response which favors the recruitment/activation of other immune
cells, such as dendritic cells [33,35]. Therefore, the positive
outcome that occurs in vivo may be achieved only in the tumor
context.
Mice adoptively transferred with Cl-IB-MECA-treated CD8+ T
cells showed a higher presence of mature LCs that could facilitate
the T cell response [34].Transfer of Cl-IB-MECA-treated CD8+ T
cells in mice receiving TNF-a mAb led to a reduced activation/
influx of mature LCs within tumor tissue, which correlated with an
impaired activity of CD8+ T cells to control tumor growth.
Depletion of CD11c+ CD207 high cells in future studies may
resolve whether the influx LC cells in response to Cl-IB-MECA is
sufficient for its anti-tumour effect or whether the local release of
TNFa by T-cells has additional effects. Taken together our in vivo
evidence demonstrates the critical role of TNF-a in the Cl-IB-
MECA-treated CD8+ T cell-induced immune response within the
Figure 4. Cl-IB-MECA stimulation of CD8+ T cells in vitro favors TNF-a production. A) A3 adenosine receptor expression by CD8+ T cells. B)
TNF-a levels in the supernatants of naı¨ve (white bars) and activated (black bars) CD8+ T cells after Cl-IB-MECA treatment measured at 24 h by ELISA.
C) INF-c production measured in the supernatants of naı¨ve (white bars) and activated (black bars) CD8+ T cells stimulated or not with Cl-IB-MECA
(0.1 mg/ml) and measured at 72 h by means of ELISA. . D), E) and F) percentage of CD69+ cells, CD25+ cells or CD27+ cells, respectively, after Cl-IB-
MECA treatment. G) MRS1191 blocked the stimulatory effect of Cl-IB-MECA on TNF-a release. Data are from two independent experiments and
represent mean 6 SEM, n = 8 for each experiment. Statistical difference was determined by Student’s t test. *p,0.05.
doi:10.1371/journal.pone.0045401.g004
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tumor lesion. However, our data cannot rule out the possibility
that Cl-IB-MECA treatment could also influence the CD8+T cell
activity in an antigen-dependent manner. This possibility using
gp100 TCR transgenic mice (pmel) as donors should be tested in
future studies.
In conclusion, our study demonstrates that adoptive transfer of
Cl-IB-MECA-treated T cells reduced melanoma growth in mice
and prolonged survival time. It is also noteworthy that a single
administration of Cl-IB-MECA may augment the protective
immunity in the melanoma, by enhancing tumor infiltration of
CD8+ T cells, which, in turn, are driven to induce a Th1-like and
cytotoxic immune microenvironment. The enhancement of the
therapeutic efficacy of CD8+ T cells by Cl-IB-MECA further
supports its utility in cancer immunotherapy.
Supporting Information
Figure S1 CD8+ T cell enrichment from naı¨ve spleen.
CD8+ T cells were negatively selected from spleen of naı¨ve
C57Bl6j mice. Purity of CD8+ T cells was checked by flow
cytometry analysis after staining with a PE-conjugated anti-CD8
antibody and was routinely around 90%. Cells were gated as
CD3+CD8+ cells.
(TIF)
Figure S2 A single injection of Cl-IB-MECA and Cl-IB-
MECA-treated CD8+ T cell transfer suppress melanoma
growth. A) and B) H&E staining and Ki67 staining of melanoma-
bearing C57Bl6i mice, respectively. C) and D) H&E staining and
Ki67 staining of melanoma-bearing Nude mice, respectively.
(Magnification: 206).
(TIF)
Figure S3 Cl-IB-MECA-treated CD8+ T cells reduce
melanoma growth. Cells were delivered by the i.v. route. Data
are from two independent experiments and represent mean 6
SEM, n = 6. Statistical difference was determined by one way
ANOVA. *p,0.05.
(TIF)
Figure S4 Cl-IB-MECA administration enhances the
presence of CD8+T cells in the tissue. Percentage of
CD3+CD8+ T cells in tumor tissue of mice receiving a single
injection of Cl-IB-MECA. Representative dot plot is shown on the
right of the graph.
(TIF)
Figure 5. Neutralization of TNF-a abrogated the anti-tumor effect of Cl-IB-MECA-treated CD8+ T cells. A) Tumor volume (mm3) in mice
receiving anti-TNF-a mAb (dashed lines) or isotype IgG control (continuous lines) and injected with Cl-IB-MECA or PBS or CD8+ T cells treated or not
with Cl-IB-MECA. B) Percentage of CD11c+CD207 high cells in the tissue of mice described above. C) Representative dot plot is shown. D) and E)
Expression of CD80 and MHC I, respectively, on CD11c+CD207 high cells in the tissue of mice described above. Data are from two independent
experiments and represent mean 6 SEM, n = 9 for each experiment. Statistical difference was determined by one way ANOVA. *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0045401.g005
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